Immutrin Raises $87M to Advance Amyloidosis Antibody Therapy
CAMBRIDGE, UK, April 8, 2026 Immutrin Ltd has successfully raised £65 million ($87 million) in an oversubscribed Series A...
rare diseases
Advertisement
ALS Research at Risk from Proposed FY27 Budget Cuts
ARLINGTON, Virginia, United States, April 7, 2026 The ALS Association has issued a strong statement warning that the proposed...
Biogen to Acquire Apellis in $5.6B Strategic Pharma Deal
CAMBRIDGE, Mass. & WALTHAM, Mass., USA — March 31, 2026 In a major biopharmaceutical industry consolidation, Biogen Inc. has...
Recordati Confirms CVC Interest in Major Pharma M&A Deal
MILAN, Italy, March 26, 2026 Recordati S.p.A. has confirmed receiving a non-binding indication of interest from CVC Capital Partners...
IMCIVREE Gains EU Momentum for Rare Obesity Disorder
Boston, March 26, 2026 In a significant advancement for rare disease therapeutics, Rhythm Pharmaceuticals has received a positive opinion...
Advertisements
Sarepta Reports Breakthrough siRNA Data in FSHD, DM1
CAMBRIDGE, Massachusetts, March 25, 2026 Sarepta Therapeutics has announced first clinical data from its next-generation siRNA pipeline, demonstrating robust...
Nxera Pharma FY2025 Results Signal Pipeline Expansion
TOKYO, Feb. 13, 2026 — Nxera Pharma Co., Ltd. reported its consolidated financial and operational results for FY2025, outlining...
KalVista Showcases EKTERLY Data at AAAAI 2026 Meet
FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world...
MIPLYFFA Real-World Data Strengthen NPC Treatment Impact
CELEBRATION, Fla., Feb. 4, 2026 —Zevra Therapeutics announced the presentation of positive new real-world data on MIPLYFFA® (arimoclomol) in...
Sensorion Secures €60M to Advance Gene Therapies for Hearing Loss
MONTPELLIER, France | January 28, 2026 — Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, announced a...
Advertisement
